Background Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory
infection (ALRI) in young children aged< 5 years. Methods We aimed to identify the global …

Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early
childhood and palivizumab is the only licensed intervention for prevention. Palivizumab …

Background Limited data are available on the economic costs of respiratory syncytial virus
(RSV) infections among infants and young children in the United States. Methods We …

Respiratory viral infections represent the leading cause of hospitalization in infants and
young children worldwide and the second leading cause of infant mortality. Among these …

Introduction: Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract
infections (LRTI) in infants, the elderly, and the immunocompromised. Although the …

Objective This article aims to compare respiratory syncytial virus (RSV) immunoprophylaxis
(IP) use and RSV hospitalization rates (RSVH) in preterm and full-term infants without …

Objective Palivizumab is a humanized monoclonal antibody approved for the prevention of
serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in …

Objective This study examined the rate, severity, and cost of respiratory syncytial virus (RSV)
hospitalizations among preterm infants 29 to 34 weeks gestational age (wGA) versus term …

Objective The objective of this study was to compare risk for respiratory syncytial virus (RSV)
hospitalizations (RSVH) for preterm infants 29 to 34 weeks gestational age (wGA) versus …

Objective The aim of this study was to compare inpatient outcomes and costs for children
with respiratory syncytial virus and congenital heart disease before and after the change in …